Insider trade

Officer sold ~$533K of COLL shares in the open market

Traded Dec 8, 2025 · Filed Dec 10, 2025

Why it stands out

Collegium Pharmaceutical's & Chief Commercial Officer sold $533K of Collegium Pharmaceutical shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$532,771

Shares × reported transaction price

Timing vs results

32 days after results of Nov 6, 2025, 80 days before results of Feb 26, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.0%	−1.8%	+3.9%
30 days	−0.4%	+0.9%	−1.3%
90 days	−26.3%	−1.9%	−24.5%
180 days	−28.9%	+7.0%	−35.8%

Past results only. Not a forecast.

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.212 to $48.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

10mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance10mo ago

10mo ago

Derivative exercise or conversion — not an open-market buy.